Pfizer announced that it is already in the process of clinical trials on its tablet-drug for COVID-19 – it has the working name PF 07321332. It is intended to stop the coronavirus from replicating in the nose, throat, and lungs, and thus prevent the development of the disease in its first stages.
Pfizer is entering the clinical trial phase of its drug for COVID-19
They are to last 173 days.
If clinical trials are positive, the drug may appear in some markets in 2021.
Pfizer developed the drug from scratch during the pandemic, with the first minimum dose ready in July 2020. By October, 100 grams of the drug had already been produced. A team of 210 scientists worked on the substance.
The company says that in preliminary in vitro tests the drug “has demonstrated antiviral activity against SARS-CoV-2” and against other coronaviruses. So, according to The Telegraph, it could also serve as a cure for common colds caused by other coronaviruses.
According to the statements by Pfizer chief scientist Mikael Dolsten, the drug would be prescription – at least in the US. However, according to the documents described by “The Telegraph”, until February 8, the drug had not yet been administered to humans, and its safety was tested on animals. They did not show any “significant risk” or safety incidents. In animals, it also did not cause any side effects at doses that are to be used in humans in clinical trials.